<DOC>
	<DOCNO>NCT02386436</DOCNO>
	<brief_summary>GSK2330811 humanise monoclonal antibody , block Oncostatin M ( OSM ) , develop treatment inflammatory fibrotic disease . This first time human study evaluate safety , tolerability , pharmacokinetic ( PK ) , pharmacodynamic ( PD ) immunogenicity profile single ascend subcutaneous ( s.c. ) dose GSK2330811 , healthy subject . This study randomise , double-blind ( sponsor open ) , placebo-controlled , single centre , single dose escalation study s.c. administration GSK2330811 healthy subject . Approximately 40 subject enrol study , across 5 cohort . Each cohort plan consist 8 subject , randomise 6 subject receive GSK2330811 2 subject receive placebo . The start dose study 0.1 milligram ( mg ) /kilogram ( kg ) s.c. single dose high dose 6 mg/kg s.c. single dose . Subjects admit clinical unit day prior dose ( Day -1 ) . On Day 1 , subject receive s.c. dose GSK2330811 placebo . Subjects remain in-patient discharged Day 8 , assessment perform . The duration study , include screening , approximately 19 week Cohorts 1 4 23 week Cohort 5 .</brief_summary>
	<brief_title>A Safety , Tolerability , Pharmacokinetics Pharmacodynamics Study GSK2330811 Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<criteria>Between 18 65 year age inclusive , time signing informed consent . Healthy determine investigator medically qualify designee base medical evaluation include medical history , physical examination , laboratory test , vital sign 12lead ECG . A subject clinical abnormality laboratory parameter ( ) is/are specifically list inclusion exclusion criterion , outside reference range population study may include investigator document find unlikely introduce additional risk factor interfere study procedure . Cohorts 14 : Body weight &lt; =100 kg body mass index ( BMI ) within range 18.5 29.9 kilogram per meter square ( kg/m^2 ) ( inclusive ) ; Cohort 5 : Body weight &lt; =80 kg BMI within range 18.5 29.9 kg/m^2 ( inclusive ) . Female subject eligible participate pregnant ( confirm negative serum [ screen ] urine [ Day 1 ] human chorionic gonadotrophin [ hCG ] test ) , lactate , least one follow condition applies : Premenopausal females one following : Documented tubal ligation , Documented hysteroscopic tubal occlusion procedure followup confirmation bilateral tubal occlusion , Hysterectomy , Documented Bilateral Oophorectomy . Postmenopausal define 12 month spontaneous amenorrhea ( questionable case blood sample simultaneous follicle stimulate hormone [ FSH ] estradiol level consistent menopause ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one highly effective contraception method wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrolment . Male subject female partner child bear potential must comply follow contraception requirement time first dose study medication 15 week dose study medication : Vasectomy documentation azoospermia . Male condom plus partner use one contraceptive option follow : Contraceptive subdermal implant meet Standard Operating Procedure ( SOP ) effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Intrauterine device intrauterine system meet SOP effectiveness criterion include &lt; 1 % rate failure per year , state product label ; Oral Contraceptive , either combined progestogen alone injectable progestogen ; Contraceptive vaginal ring ; percutaneous contraceptive patch . These allow method contraception effective use consistently , correctly accordance product label . The investigator responsible ensure subject understand properly use method contraception . Capable give sign informed consent include compliance requirement restriction list consent form protocol . Subjects value alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , creatinine upper limit normal ( ULN ) ; value platelet haemoglobin low limit normal ( LLN ) ; normal range value white blood cell ( WBC ) , reticulocytes , serum sodium , serum potassium . Any history gastreointestinal bleeding disorder peptic ulcer disease , haematemesis gastrointestinal bleeding . Subjects medical condition associate increase risk complication bleed . A history haematological disease , anaemia , acquire platelet disorder coagulation disorder , include druginduced thrombocytopaenia , idiopathic thrombocytopaenia von Willebrand 's disease . Donation blood excess 500 mL within 56 day period prior dose . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Clinically significant finding ECG . QT duration correct heart rate Fridericia 's formula ( QTcF ) &gt; 450 millisecond ( msec ) . History Tuberculosis ( TB ) positive QuantiFERON®TB Gold ( trademark Quiagen ) test screening : If QuantiFERON®TB Gold test indeterminate , repeat ; must clinical evidence TB physical examination subject . A history carcinoma situ malignant disease , exception basal cell carcinoma completely excise prior study . Subject unable abstain use medication know affect platelet clot function , include aspirin nonsteroidal antiinflammatory drug ( NSAIDs ) , within five halflives last dose platelet affect medication prior study day 1 , end study followup . History regular alcohol consumption within 6 month study define average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram alcohol : halfpint ( ~240 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . Smokers would able refrain smoke whilst phase I unit . History sensitivity component study medication , history drug allergy , opinion investigator Medical Monitor , contraindicate participation . History severe drug allergy , include type I hypersensitivity reaction parenteral administration contrast agent , human murine proteins monoclonal antibody . History opportunistic infection within 1 year screen recurrent infection , determine investigator . History serious infection result intravenous antibiotic and/or hospitalisation within 6 month prior screen . Active bacterial infection , viral infection , fever &gt; 38 degree centigrade within 14 day prior Day 1 . A history frequent reactivation herpes simplex . Presence hepatitis B surface antigen ( HBsAg ) positive hepatitis C antibody test result screen within 3 month prior dose study treatment . A positive prestudy drug/alcohol screen . A positive test human immunodeficiency virus ( HIV ) antibody screen . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical four new biological entity within 12 month prior first dose day . Subject unable abstain travel region high endemic infection , determine investigator , duration study . Subject unable abstain immunise liveattenuated vaccine 4 week prior day 1 , end follow . Subject unable refrain take prescription nonprescription drug ( include vitamin dietary herbal supplement ) , within 7 day prior first dose study medication completion followup visit , unless opinion Investigator sponsor medication interfere study . For cohort include suction blister ( Cohorts 35 ) : Presence skin abnormality would either interfere study procedure ( example ; tattoo , naevi , sun burn/sun bed use within 7 day ) increase risk subject ( example : history keloid , skin allergy , hypersensitivity contact dermatitis , include previous reaction dressing use study ) , determine investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>GSK2330811</keyword>
	<keyword>Dose Escalation</keyword>
	<keyword>Safety</keyword>
	<keyword>First Time Human</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>